Crossmark

Genotype-guided switch from ravulizumab to satralizumab in aquaporin-4–IgG–positive neuromyelitis optica spectrum disorder: a case of C5 polymorphism-associated ravulizumab resistance

Crossref DOI link: https://doi.org/10.1007/s10072-026-08993-7

Published Online: 2026-03-28

Published Print: 2026-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Naito, Hiroyuki https://orcid.org/0000-0002-8080-1099
Sugimoto, Takamichi

Yamazaki, Yu

Maruyama, Hirofumi
License Information

Text and Data Mining valid from 2026-03-28

Version of Record valid from 2026-03-28
More Information

Article History

Received: 21 January 2026

Accepted: 17 March 2026

First Online: 28 March 2026

Declarations

:

: Written informed consent was obtained from the patient for the publication of this case report.

: The authors declare that they have no conflicts of interest.

Document is current

Any future updates will be listed below